drugset / Trial / NCT06234748

Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer

NCT06234748 ↗

Phase 2 Active not recruiting 19 enrolled University of Michigan Rogel Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

This study seeks to study the population of HPV-related oropharynx cancer patients that appear to be at highest risk for treatment failure with loco-regional failure and distant metastases including cT4 or cN3. The study team aims to determine if it is feasible to use multi-modality imaging (both DCE MRI and FDG-PET) to optimize the radiation boost in high risk p16+ OPSCC with similar or decreased toxicity compared to historic standard therapy.

Timeline

Start
2023-12-20
Primary completion
2028-07
Completion
2028-07

Drugs

EvaluationDrugModalityDoseRoute
Background Carboplatin Small molecule — —
Background Cisplatin Other / unclassified — —